Unique properties of IgG4 antibody and its clinical application in autoimmune pancreatitis

Treatment approaches in autoimmune pancreatitis (Review)

Autoimmune pancreatitis (AIP) is a rare disease. There are two distinct types of AIP: AIP type 1 (AIP-1), a pancreatic manifestation of a multi-organ disease linked to immunoglobulin (Ig)G4, and AIP type 2 (AIP-2), a pancreas-specific disease unrelated to IgG4. The usual course of treatment for AIP is oral corticosteroid medication. Rituximab has also been recommended for recurrent AIP-1 in order to initiate remission and provide ongoing treatment. Immunomodulators such as azathioprine are used to keep certain patients in remission. Evaluation also takes into account a number of pharmacological alternatives, including biologic drugs like anti-tumor necrosis factor therapy, a safe and efficient second-line treatment for AIP-2 relapse or steroid dependence. Corticosteroids and immunosuppressants, which are poorly tolerated due to considerable side effects, are being replaced by other biologic drugs, which may offer a beneficial therapeutic alternative.

Autoimmune Pancreatitis: From Pathogenesis to Treatment

Autoimmune pancreatitis (AIP) is a rare disease. The diagnosis of AIP is difficult and should be made by a comprehensive evaluation of clinical, radiological, serological, and pathological findings. Two different types of AIP have been identified: autoimmune pancreatitis type 1 (AIP-1), which is considered a pancreatic manifestation of multiorgan disease related to IgG4, and autoimmune pancreatitis type 2 (AIP-2), which is considered a pancreas-specific disease not related to IgG4. Although the pathophysiological conditions seem to differ between type 1 and type 2 pancreatitis, both respond well to steroid medications. In this review, we focused on the pathogenesis of the disease to develop a tool that could facilitate diagnosis and lead to the discovery of new therapeutic strategies to combat autoimmune pancreatitis and its relapses. The standard therapy for AIP is oral administration of corticosteroids. Rituximab (RTX) has also been proposed for induction of remission and maintenance therapy in relapsing AIP-1. In selected patients, immunomodulators such as azathioprine are used to maintain remission. The strength of this review, compared with previous studies, is that it focuses on the clear difference between the two types of autoimmune pancreatitis with a clearly delineated and separate pathogenesis. In addition, the review also considers various therapeutic options, including biologic drugs, such as anti-tumor necrosis factor (TNF) therapy, a well-tolerated and effective second-line therapy for AIP type 2 relapses or steroid dependence. Other biologic therapies are also being explored that could provide a useful therapeutic alternative to corticosteroids and immunosuppressants, which are poorly tolerated due to significant side effects.

Atypical enhanced computed tomography signs of pancreatic cancer and its differential diagnosis from autoimmune pancreatitis

Background

To analyze the atypical enhanced computed tomography (CT) signs of pancreatic cancer (PC) and compare them with those of autoimmune pancreatitis (AIP) to explore the differential diagnosis value of CT.

Methods

The clinical data of 36 AIP (AIP group) and 38 PC patients (PC group), who were admitted to our hospital from January 2013 to June 2020 and confirmed by surgical biopsy or hormone therapy, were retrospectively analyzed. Participants in both groups were examined by CT, the imaging signs of the 2 groups were analyzed, and the results of CT examination were compared.

Results

In the PC group, the density of the lesions on the CT scan was mostly reduced, the pancreas was not swollen, and the kidneys were not involved. The bile duct wall was thickened with a sausage-like appearance, enveloped edges were rare, blood vessels were invaded, lymph nodes were enlarged, and the pancreatic duct was truncated. The findings of the AIP group were the opposite. The difference in the proportion of participants with the above-mentioned CT features between the 2 groups was statistically significant (P<0.05). The shape of the lesions in the AIP group was mainly elongated, of uneven density, and the density of enhanced scanning was medium to high. The predominant shape of the lesions in PC participants was spherical, and the density was uniform. The enhanced scan was mainly low-density. The difference in shape and density between the 2 groups was also statistically significant (P<0.05). The CT values of the plain scan, intravenous phase, and delayed phase in the AIP group were significantly higher than those in the PC group (P<0.05).

Conclusions

The imaging signs of AIP and PC overlap. Examination with CT is of great value in the differential diagnosis between AIP and PC. Familiarity with and mastery of the CT signs of AIP and PC can help to improve the accuracy of clinical diagnosis and provide a reliable basis for patients' follow-up treatment.

The Cellular and Molecular Bases of Allergy, Inflammation and Tissue Fibrosis in Patients with IgG4-related Disease

IgG4-related disease (IgG4-RD) is a spectrum of complex fibroinflammatory disorder with protean manifestations mimicking malignant neoplasms, infectious or non-infectious inflammatory process. The histopathologic features of IgG4-RD include lymphoplasmacytic infiltration, storiform fibrosis and obliterative phlebitis together with increased in situ infiltration of IgG4 bearing-plasma cells which account for more than 40% of all IgG-producing B cells. IgG4-RD can also be diagnosed based on an elevated serum IgG4 level of more than 110 mg/dL (normal < 86.5 mg/mL in adult) in conjunction with protean clinical manifestations in various organs such as pancreato–hepatobiliary inflammation with/without salivary/lacrimal gland enlargement. In the present review, we briefly discuss the role of genetic predisposition, environmental factors and candidate autoantibodies in the pathogenesis of IgG4-RD. Then, we discuss in detail the immunological paradox of IgG4 antibody, the mechanism of modified Th2 response for IgG4 rather than IgE antibody production and the controversial issues in the allergic reactions of IgG4-RD. Finally, we extensively review the implications of different immune-related cells, cytokines/chemokines/growth factors and Toll-like as well as NOD-like receptors in the pathogenesis of tissue fibro-inflammatory reactions. Our proposals for the future investigations and prospective therapeutic strategies for IgG4-RD are shown in the last part.